/
Neuraxis, Inc. ( we , us , the Company or Neuraxis ) is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and additional clinical trials of…
The business is unprofitable at the operating level (-219.37% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 32.9% YoY with margins expanding 47.1pp.
ROIC dropped from -129.00% to -132.21%, capital efficiency is deteriorating. Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$4M
▲ +32.9% YoY
Net Income (TTM)
-$7M
▲ +5.4% YoY
Op. Margin
-169.93%
▲ +47.1pp YoY
ROIC
-132.55%
▼ -3.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▼ -5.5% YoY
Op. Cash Flow (TTM)
-$6M
▼ -5.5% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$7M
3Y CAGR: +10.0%
Continue Research